SARS-CoV-2 Proteome-Wide Analysis Revealed Significant Epitope Signatures in COVID-19 Patients

TY - JOUR

T1 - SARS-CoV-2 Proteome-Wide Analysis Revealed Significant Epitope Signatures in COVID-19 Patients

AU - Schwarz, Tatjana

AU - Heiss, Kirsten

AU - Mahendran, Yuvaraj

AU - Casilag, Fiordiligie

AU - Kurth, Florian

AU - Sander, Leif E

AU - Wendtner, Clemens-Martin

AU - Hoechstetter, Manuela A

AU - Müller, Marcel A

AU - Sekul, Renate

AU - Drosten, Christian

AU - Stadler, Volker

AU - Corman, Victor

N1 - Copyright © 2021 Schwarz, Heiss, Mahendran, Casilag, Kurth, Sander, Wendtner, Hoechstetter, Müller, Sekul, Drosten, Stadler and Corman.

PY - 2021

Y1 - 2021

N2 - The WHO declared the COVID-19 outbreak a public health emergency of international concern. The causative agent of this acute respiratory disease is a newly emerged coronavirus, named SARS-CoV-2, which originated in China in late 2019. Exposure to SARS-CoV-2 leads to multifaceted disease outcomes from asymptomatic infection to severe pneumonia, acute respiratory distress and potentially death. Understanding the host immune response is crucial for the development of interventional strategies. Humoral responses play an important role in defending viral infections and are therefore of particular interest. With the aim to resolve SARS-CoV-2-specific humoral immune responses at the epitope level, we screened clinically well-characterized sera from COVID-19 patients with mild and severe disease outcome using high-density peptide microarrays covering the entire proteome of SARS-CoV-2. Moreover, we determined the longevity of epitope-specific antibody responses in a longitudinal approach. Here we present IgG and IgA-specific epitope signatures from COVID-19 patients, which may serve as discriminating prognostic or predictive markers for disease outcome and/or could be relevant for intervention strategies.

AB - The WHO declared the COVID-19 outbreak a public health emergency of international concern. The causative agent of this acute respiratory disease is a newly emerged coronavirus, named SARS-CoV-2, which originated in China in late 2019. Exposure to SARS-CoV-2 leads to multifaceted disease outcomes from asymptomatic infection to severe pneumonia, acute respiratory distress and potentially death. Understanding the host immune response is crucial for the development of interventional strategies. Humoral responses play an important role in defending viral infections and are therefore of particular interest. With the aim to resolve SARS-CoV-2-specific humoral immune responses at the epitope level, we screened clinically well-characterized sera from COVID-19 patients with mild and severe disease outcome using high-density peptide microarrays covering the entire proteome of SARS-CoV-2. Moreover, we determined the longevity of epitope-specific antibody responses in a longitudinal approach. Here we present IgG and IgA-specific epitope signatures from COVID-19 patients, which may serve as discriminating prognostic or predictive markers for disease outcome and/or could be relevant for intervention strategies.

KW - Adult

KW - Antibodies, Viral/immunology

KW - COVID-19/immunology

KW - Epitopes/immunology

KW - Female

KW - Humans

KW - Immunity, Humoral

KW - Immunoglobulin A/immunology

KW - Immunoglobulin G/immunology

KW - Male

KW - Proteome/immunology

KW - SARS-CoV-2/immunology

U2 - 10.3389/fimmu.2021.629185

DO - 10.3389/fimmu.2021.629185

M3 - SCORING: Journal article

C2 - 33833755

VL - 12

SP - 629185

JO - FRONT IMMUNOL

JF - FRONT IMMUNOL

SN - 1664-3224

ER -